Coronary Artery Disease Regression
Convincing Evidence for the Benefit of Aggressive Lipoprotein Management H. Robert Superko, MD; Ronald M. Krauss, MD Background Numerous reports suggest that coronary artery disease can regress with lipoprotein manipulation. Many of these reports lack control groups and contain relatively small numbers.
Methods and Results Ten randomized controlled clinical trials using coronary arteriography to assess the effect of lipoprotein manipulation on the rate of progression and regression of atherosclerosis have been either published or reported as an abstract at a national meeting. These studies were critically reviewed for individual differences and combined clinically applicable lessons. These trials involved a total of 2095 subjects and have consistently reported reduction in the percentage of patients arteriographically defined as progressing (mean, 23.6%) and an increase in the percentage regressing (mean, 20.0%) compared with control groups. Compared with large clinical trials using clinical end points, lipoprotein change was greater, achieving on average a 28% reduction in low-density lipoprotein cholesterol, 11% reduction in triglycerides, and 1% increase in high-density lipoprotein cholesterol compared with control groups. Four investigations used a nonpharmacological approach, and seven used single and multiple drug therapy combined with diet. Despite the relatively brief treatment time of often 2 to 4 years, clinical events were fewer in the treatment groups; within some studies, this reached statistical significance. Side effects from the different therapies were tolerated by most patients, and severe adverse clinical events were few.
Conclusions These trials present convincing evidence that aggressive lipoprotein manipulation can result in improved arteriographic measurements and fewer cardiovascular events in a relatively short period of time of 2 to 4 years. Extrapolation of this information to the larger population with 17 These clinical trials require thousands of participants and 5 to 10 years of therapy to demonstrate a significant difference in clinical events between the control and treatment groups.
Measurements of change in coronary artery disease (CAD) severity, quantified by repeat arteriograms, can test the effectiveness of an intervention in a shorter time span and with smaller study groups than those required for clinical end-point trials. The "natural" rate of progression of atherosclerotic coronary artery occlusion has been estimated as approximately a 1.5% reduction in minimal artery diameter per year. 18 Comparison between a control and treatment group is necessary to account for variation in the rate of natural progression as well as the precision of arteriographic measurements within individual studies. [18] [19] [20] Although lipoproteins are the focus of this review, arteriographically defined progression of atherosclerosis has been related to a number of nonlipid variables, including the number of diseased vessels, age, and smoking status.2' Coronary artery bypass surgery (CABS) is an important variable, since the rate of progression is reported to be three to six times greater in grafted versus ungrafted vessels, and without intervention, 45% of grafts have significant occlusive disease 5 years after surgery. 22 Ten randomized intervention trials using coronary arteriography as an end point have indicated that the rate of atherosclerosis progression can be reduced and that reduction in coronary lumen obstruction is possible (Table  1) . [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] The evidence that an aggressive lipoprotein treatment program is beneficial with regard to atherosclerosis in patients with CAD is convincing and indicates that adequate CAD management in the 1990s should include aggressive lipoprotein diagnosis and treatment. Uncontrolled studies have suggested that arteriographic regression is possible. 46 The first statistically significant effect on arteriographically determined atherosclerosis in a randomized trial was reported in femoral arteries and was confirmed by a subsequent investigation.4748 Because of the arterial bed studied, these trials will not be discussed further in this review of CAD. Three investigations used a nonpharmacological therapy that included diet plus fiber, exercise, and partial ileal bypass.27,31,32 Eight investigations used single or combination drug therapy, and one of these had both a diet and a drug group. 23, 25, 26, Because of the different therapeutic approaches, the results of these investigations will be grouped into nonpharmacological investigations (Table 2 ) and pharmacological investigations (Table 3) . One trial, the Program on the Surgical Control of the Hyperlipidemias (POSCH), used a unique surgical intervention and will be included in the pharmacological trials because of the aggressive nature of the intervention. In addition to the unweighted average mean differences between groups, in Tables 2  and 3 , the weighted differences in the percentage of subjects with progression or regression of disease, where each treatment minus control group difference is given a weight inversely proportional to the variance in each study, are presented. 49 The percent changes in lipoproteins are presented as unweighted differences in Tables  4 and 5 . It is not possible to calculate weights for the changes in plasma lipoproteins in each study because complete information on the SDs for the change scores is not available for all studies. (Figure) . The difference in the percentages of treatment and control subjects revealing progression or regression averaged 24% more progression in the control groups and 20% more regression in the treatment groups. In the treatment groups, on average, 29% of patients were classified as having proAlthough the arteriographic methodology and definition of progression or regression are by no means uni- Nonpharmacological Investigations Three investigations that used a nonpharmacological or nonsurgical intervention have been reported (Table  1 ). The Lifestyle Heart Trial studied patients assigned to a low-fat vegetarian diet with specially prepared meals, smoking cessation, moderate exercise, and stress management and compared the results with those from patients in a usual-care group.27 Only 28 (53%) in the experimental group and 20 (42%) in the control group agreed to participate after randomization, which resulted in a trial design that may have biased the results because of a lack of adequate randomization.
The St Thomas Arteriographic Regression Study (STARS) investigation involved 90 hypercholesterolemic men and a 3-year interval between coronary arteriography in three groups: a usual-care (control) group; a group treated with a low-fat (27% of dietary energy), high-fiber diet only; and a third group treated with the same diet but with the addition of cholestyramine. 31 This investigation compared the effectiveness of diet plus fiber therapy to diet plus a resin in a controlled, randomized trial.
The Heidelberg Exercise/Diet Study used digital coronary arteriography to assess the effect of 1 year of moderate physical activity and a low-fat diet in 113 men with documented CAD.32 Subjects were randomly assigned to either a control group, who received an AHA phase I diet, exercise advice, and 1 week in a metabolic teaching ward but no adherence help, or to an intervention group, who received an AHA phase III diet, 3 weeks in a metabolic teaching ward, and a physical activity program that involved 30 minutes of daily home exercise along with two 60-minute group training sessions per week.
After 1 year in the Lifestyle Heart Trial, progression was reported in 18% of the treated group compared with 53% of the control group, and regression was reported in 82% of the treated group compared with 42% of the control group. These results should be interpreted in light of the trial design difficulties. In STARS, progression was reported in 46% of the control group and 15% of the diet plus fiber group. Regression was reported in 4% of the control group and 38% of the diet plus fiber group. In this investigation, the mean absolute width of the coronary segments decreased significantly less (P<.05) in both treatment groups compared with the control groups. In the Heidelberg investigation, progression was reported in 48% of the control group and 23% of the diet/exercise group. Regression was reported in 17% of the control group and 32% of the diet/exercise group. These differences were significant (P<.05). The dose of physical activity was found to be important, and intense physical activity (2204 kcal/wk) resulted in regression, moderate activity (1533 kcal/wk) in no change, and little activity (1022 kcal/wk) in arteriographic progression (P<.005).50 As a group, these nonpharmacological treatments increased the chance of arteriographic regression in the treatment compared with the control group by 15% to 40% and reduced the chance of progression from 25% to 35%.
Pharmacological Investigations
The first randomized coronary arteriography trial was conducted by the National Heart, Lung, and Blood Institute (NHLBI) in 116 male and female subjects classified as having type II hyperlipidemia and treated with diet therapy and either placebo or cholestyramine for 5 years.23'24 Sample size calculations indicated that 250 subjects would be required to approach a 90% chance of detecting a cholestyramine-induced change in the reduction of the rate of progression from 60% to 40%. Unfortunately, the major limitation of this investigation was the inability to recruit the 250 subjects, and only 143 were recruited. Nevertheless, multivariate analyses supported the hypothesis (P<.05) that treatment with cholestyramine would be beneficial. However, among standard lipoprotein measurements, only change in HDL cholesterol correlated with all definitions of arteriographic change. In the lowest tertile of HDL cholesterol change (>2.6 mg/dL decrease), 38% of the subjects demonstrated definite progression, and in the upper tertile (>10.25 mg/dL increase), 16% demonstrated progression (P<.05). Although no relation existed between absolute levels of LDL cholesterol and arteriographic change, arteriographic benefit was associated with a reduction in IDL (Svedberg flotation [Sf] unit, 12 to 20) and small LDL (Sf, 0 to 7).51
However, when the tertile with the greatest LDL cholesterol change was compared with the other two tertiles, there was a statistically significant relation between rate of CAD progression and LDL cholesterol change.24 For lesions of >50% stenosis, significantly more subjects (P<.05) in the control group demonstrated progression. The first investigation to report significant arteriographically determined CAD regression was the Cholesterol Lowering and Atherosclerosis Study (CLAS In SCOR, the change in percent area stenosis was better correlated with on-trial LDL cholesterol levels (r=.28, P=.018) than with change from baseline, which suggests that absolute LDL cholesterol values may be a better clinical goal than percent change from baseline, but this contrasts with the NHLBI-II and FATS findings.24,26,29
As noted above in "Nonpharmacological Investigations," STARS involved 90 hypercholesterolemic men and a 3-year interval between coronary arteriographies.31 Progression was reported in 46% of the control group and 12% of the diet plus cholestyramine group. Regression was reported in 4% of the control group and 33% of the diet plus cholestyramine group. The mean absolute width of the coronary segments decreased significantly more (P<.05) in the treatment groups. Despite differences in plasma lipoprotein and lipid changes from the nonpharmacological and pharmacological treatments, the amounts of disease progression and regression were remarkably similar in the two treatment groups (Tables 2 and 3 23 The recent findings from MARS also suggest that significant benefit is seen in lesions >50% obstructed at baseline. However, it has also been reported from MARS that in lesions <50% obstructed at baseline, arteriographic benefit is seen primarily in patients who exhibited a reduction in plasma triglyceride concentration. 57 The degree of hypercholesterolemia at baseline may not correlate with the beneficial effect of lipid lowering. In CLAS, both new atheroma formation in native coronary arteries and changes in bypass grafts were significantly less (P<.04) in the treatment group.25 When subjects were stratified by baseline total cholesterol into "low" (185 to 240 mg/dL) and "high" (241 to 350 mg/dL) groups, this treatment effect remained significant (P<.03) in both groups.
Blood Lipid Change
The patient populations and therapies were quite heterogeneous among the trials; thus, it is not surprising that substantial differences in lipoprotein response to therapy were reported. However, one of the common aspects of these trials is aggressive lipoprotein management and significantly greater change in lipoprotein concentrations compared with clinical end-point trials. Moreover, most control groups in the arteriographic trials received some blood cholesterol-lowering advice, diet, or medication compared with the true placebo nature of the clinical end-point trial control groups. Thus, many control groups received treatment comparable to current community standards.
One of the important observations from these trials is the relative amount of plasma lipid change achieved in the nonpharmacological trials compared with the pharmacological trials (Tables 4 and 5 ). The pharmacological group showed a 17% greater triglyceride reduction, an 8% greater total cholesterol reduction, a 13% greater LDL cholesterol reduction, and a 14% greater HDL cholesterol increase compared with the nonpharmacological group.
From epidemiological trials, it is established that the absolute LDL cholesterol concentration is related to CAD risk, but in a CAD population, "normal" cholesterol concentrations do not offer protection against future events.58 For this reason, arteriographic investigations that studied hypercholesterolemic patients may generate results different from those that investigated CAD patients with relatively "normal" cholesterol concentrations. Of the three nonpharmacological trials, one had a baseline mean LDL cholesterol in the treatment group of 151 mg/dL, and the other two were 164 and 193 mg/dL (Table 4) . Of the eight studies using medications, seven studied subjects with mean LDL cholesterol > 160 mg/dL (average LDL cholesterol, 213 mg/dL), but only two studied patients with CAD and a mean LDL cholesterol <160 mg/dL (the two treatment arms of FATS are counted as one study) ( Table 5 ). The following discussion is based on the differences achieved between the treatment and control groups.
LDL
In the nonpharmacological study treatment groups, LDL cholesterol was reduced by a mean of 20% with a range of 9% to 37%. Although differences in study design and methodology may account for this wide variation, the results confirm that substantial LDL cholesterol reduction can be achieved by nonpharmacological means.
In the pharmacological studies that investigated CAD patients with mean LDL cholesterol <160 mg/dL, the average percent difference in LDL cholesterol reduction between the treatment and control groups was 28%, and the average mean treatment LDL cholesterol in the treatment groups was 108 mg/dL. 30 The triglyceride and HDL cholesterol responses were dependent on the therapeutic intervention. In the nonpharmacological trials, triglyceride concentration was increased (compared with the control group) by a mean of 2% but ranged from -18% to + 13% (Table 4 ). HDL cholesterol increased by a mean of 1%, with a range of 0% to +2%. In the study using the most aggressive exercise approach (Heidelberg), triglycerides were reduced 24%, with a 2% HDL cholesterol increase.32
In the pharmacological trials, triglyceride and HDL cholesterol changes were in large part dependent on the medications used. In the three investigations that routinely used nicotinic acid (CLAS, FATS, and SCOR), HDL cholesterol increased on average 31 
Clinical Events
More important than arteriographic improvement is the effect of treatment on the incidence of clinical events. In the large, nonarteriographic, cholesterollowering clinical end-point trials, 5 to 10 years of follow-up in study groups numbering in the thousands was necessary to detect a significant difference in clinical events.12-14 In the therapeutically more aggressive trials that used arteriographic change as the end point, the need for large study groups and many years of follow-up were dramatically reduced, yet some demonstrated reductions in clinical end points. Despite differences in study design including duration, 6 of the 10 studies report clinical events in a manner that can be summarized (Table 6) .
POSCH was the longest study, with a mean follow-up of 9.7 years.28 Not surprisingly, the largest incidence of cardiac events was recorded in this study. Between 
Side Effects
Side effects were related to the specific therapeutic intervention (Table 7) . For the surgical therapy used in POSCH, diarrhea and watery or frothy stools were significantly more common (P<.0001) in the treatment group, as were kidney stones and gallstones (P<.0001). 28 Abdominal surgery was performed in 13.5% of subjects because of symptoms of bowel obstruction, and 3.6% required surgical correction. In the Heidelberg trial, two subjects experienced clinical events (ventricular tachycardia and sudden death) associated with exercise. 32 In larger studies, exercise in a cardiac population has been shown to be relatively safe. 54 Bile acid-binding resin use was associated with constipation and gastrointestinal distress. In CLAS, recurrent constipation was reported in 7.5% of the treatment and 2.1% of the placebo group, and 26% of FATS 
Issues Affecting Interpretation of the Studies
Arteriographic measurement methodology is an important difference between all the studies and may explain some of the variation in results reported as percent regression or percent progression. The clinical significance of the arteriographic change has been reviewed in two recent publications.63 '65 It is important that study subjects be randomly allocated to the treatment and control groups to avoid possible bias. All but one of these investigations achieved successful randomization. A weakness of the Lifestyle Heart Trial is unsuccessful randomization. Unfortunately, of the 94 eligible subjects assigned to the control or intervention groups, only 48 agreed to continue following the assignment. The 49% dropout rate seriously weakens the basic trial design and makes it difficult to describe it as a randomized trial. This situation raises the important question of bias caused by individuals selecting themselves for a specific group, as suggested by the high dropout rate. At baseline, a significant difference existed between treatment and control groups in HDL cholesterol and apo A-I. A weakness of any multifactorial trial involves the difficulty in quantifying the effect of the various interventions. This problem is compounded in this trial because of the use of stress management techniques and exercise, which are difficult to quantify. The The number of subjects in an investigation should be determined before the study by the use of statistical power calculations. The importance of this is illustrated by the difficulty in interpreting the NHLBI-II trial because of a loss of 19% of the subjects for repeat arteriograms.
Sex differences may exist in CAD progression and regression. SCOR was the only investigation to have similar numbers of men and women. The results suggest that a sex difference may exist.
Durations of the investigations varied from 1 to > 10 years. The longer the trial, the more likely it is that group differences will be seen. Most therapies were directed at a reduction in LDL cholesterol through drug or lifestyle therapy. The cumulative results indicate that a reduction in the rate of progression of CAD can be achieved with a variety of methods. A unique benefit of POSCH is the 100% compliance rate once the surgical treatment is complete. A weakness of this approach is the applicability to routine clinical care. It is unclear how many subjects could adhere to or afford a strict diet/lifestyle approach as used in the Heidelberg and Lifestyle studies. Although niacin and resins are excellent medications, subjects in the CLAS investigation were screened for niacin tolerance before entry, and in STARS, only subjects who agreed to remain on cholestyramine for 3 years were entered. Of all the investigations, SCRIP came closest to typical aggressive clinical care, since it used a combination of diet, exercise, weight reduction, smoking cessation, and multiple lipidlowering drug use. However, because of this approach, benefit cannot be attributed to a specific intervention. A formal weakness in the control groups is that all received some form of diet/lifestyle advice, and many were given the opportunity to be treated with a bile acid-binding resin. The usual-care patients in SCRIP and POSCH were treated by their personal physicians. Thus, the studies were not strictly placebo controlled, and this may have weakened the magnitude of the differences from the treatment groups.
The type of patient population studied can affect the results. The greater the risk of a population, the greater the probability that an intervention will have the desired result. Patients with CAD were studied in NHLBI-II, CLAS, Lifestyle, Heidelberg, POSCH, FATS, STARS, MARS, and SCRIP. CLAS had the additional benefit of enrolling subjects who had undergone CABS and could collect information on the effect of treatment on vein grafts. Because of the presence of CAD, these studies collected information on both secondary prevention of arteriographic change and clinical events in a population at high risk for events. SCOR investigated individuals with heterozygous familial hypercholesterolemia but no documented CAD at entry. Thus, one would expect fewer clinical events in SCOR, but the study gives important insight into the arteriographic extent of CAD in an asymptomatic hypercholesterolemic population.
Clinical Lessons
The consistent clinical lesson from these trials is that aggressive lipoprotein manipulation can significantly reduce CAD progression, promote regression, and reduce clinical events in a relatively short period of time. There was a consistent relation between LDL cholesterol or apo B reduction and arteriographic improvement, whereas in several, reduction in triglycerides and increase in HDL cholesterol were also associated with arteriographic change. Each 
Future Directions in Intervention Trials
Much work remains to be done to define more precisely which patient subgroups will benefit most from which single or combination therapy. It is no longer adequate to define improvement as changes in total cholesterol, LDL cholesterol, HDL cholesterol, or triglycerides. Detailed lipoprotein analysis can enhance the clinician's ability to correctly identify the lipoprotein abnormality and prescribe the correct therapy that will be physiologically and economically effective. The potential importance of subclass distribution differences is indicated by the results of the NHLBI-II investigation, which revealed significantly greater reduction in "small" LDL and IDL in patients who had arteriographically determined stable CAD compared with patients who had disease progression, and the results of STARS, which suggest that small LDL is the lipoprotein subfraction most strongly associated with arteriographic change.5l160 Other 
